Answers are grounded in this paper and cite their sources.
Melanocytomas have been defined as a category of intermediate melanocytic tumors that are situated biologically and genetically between benign nevi and malignant melanomas. Although melanocytomas typically display low-grade clinical behavior, their exact risk of malignant progression remains uncertain. Since the WHO introduced this concept in 2018, there have been substantial advances in understanding their genetic complexity and diagnostic challenges. Reduced inter-observer variability and advanced molecular diagnostics, including next-generation sequencing and copy number variation analysis, can support clinical decisions for management of melanocytomas. This literature review summarizes advances in understanding melanocytoma biology, focusing specifically on WHO pathways 1, 4, 7 and 8, which encompass clinically relevant entities such as Wnt-activated melanocytomas, BAP1-inactivated lesions, pigmented epithelioid melanocytomas, Spitz tumors, congenital nevi and "blue pathway" melanocytic tumors. In particular, we highlight key molecular features that have been linked with the presence of risk of progression to metastatic disease, including gene mutations (e.g., TERT promoter mutations, homozygous CDKN2A deletions, SF3B1 mutation and secondary mutations in BAP1 outside of pathway I) and copy number variations involving parts of the genomes pivotal for melanoma biology. Despite recent progress, further studies are still required to fully characterize the molecular landscape of melanocytomas, aiming to optimize clinical guidelines, reduce diagnostic uncertainty and facilitate appropriate treatment strategies.
No takes yet. Share an insight, caveat, or question.
Souverijns et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: